Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | CDA | P32320 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19277294 | 1.00 | LMNA (0.37) | LMNACYP2C9AKR1C3AKR1C2KMT2A | |
| SCHEMBL27106788 | 0.88 | KMT2A (0.42) | LMNACYP2C9AKR1C3KMT2AMEN1 | |
| SCHEMBL27106792 | 0.88 | KMT2A (0.42) | LMNACYP2C9AKR1C3KMT2AMEN1 | |
| SCHEMBL31655180 | 0.79 | KMT2A (0.38) | LMNACYP2C9AKR1C3KMT2AMEN1 | |
| SCHEMBL17185327 | 0.78 | AKR1C3 (0.32) | AKR1C3AKR1C2NPC1RAB9A | |
| SCHEMBL21740357 | 0.78 | RAB9A (0.34) | AKR1C3AKR1C2KMT2AMEN1NPC1 | |
| SCHEMBL21739122 | 0.78 | RAB9A (0.34) | AKR1C3AKR1C2KMT2AMEN1NPC1 | |
| SCHEMBL19276941 | 0.78 | RAB9A (0.34) | AKR1C3AKR1C2KMT2AMEN1NPC1 | |
| SCHEMBL25396281 | 0.77 | POLB (0.40) | AKR1C3AKR1C2KMT2AMEN1NPC1 | |
| SCHEMBL20590486 | 0.77 | POLB (0.40) | AKR1C3AKR1C2KMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2023-12-07 | — | — | US | disclosed |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2023-07-18 | — | — | US | disclosed |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2021-07-29 | — | — | US | disclosed |
| CN-112898309-A | Tricyclic compounds as immunomodulators | 正大天晴药业集团股份有限公司 | 2021-06-04 | — | — | CN | disclosed |
| US-10851057-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2020-12-01 | — | — | US | disclosed |
| EP-3310441-B1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | 89BIO LTD (IL) | 2020-07-29 | — | — | EP | disclosed |
| US-10221135-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2019-03-05 | — | — | US | disclosed |
| EP-3418282-A1 | TRICYCLIC COMPOUND SERVING AS IMMUNOMODULATOR | Chai Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2018-12-26 | — | — | EP | disclosed |
| US-20180179159-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2018-06-28 | — | — | US | disclosed |
| EP-3310441-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | Cephalon, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9902696-B2 | 1,4-substituted piperidine derivatives | CEPHALON, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| WO-2017140274-A1 | TRICYCLIC COMPOUND SERVING AS IMMUNOMODULATOR | 正大天晴药业集团股份有限公司 | 2017-08-24 | — | — | WO | disclosed |
| US-20160368874-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2016-12-22 | — | — | US | disclosed |
| WO-2016205633-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | LMNA 1574/4885CYP2C9 252/4885AKR1C3 508/4885 |
| US-20160368874-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | FASN, CES1, CPT1A | LMNA 1574/4885CYP2C9 252/4885AKR1C3 508/4885 |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | LMNA 1574/4885CYP2C9 252/4885AKR1C3 508/4885 |
| US-10221135-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | LMNA 1574/4885CYP2C9 252/4885AKR1C3 508/4885 |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | LMNA 1574/4885CYP2C9 252/4885AKR1C3 508/4885 |
| US-10851057-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | LMNA 1574/4885CYP2C9 252/4885AKR1C3 508/4885 |
| US-20180179159-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | FASN, CES1, CPT1A | LMNA 1449/4885CYP2C9 259/4885AKR1C3 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.